Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Forty Creek Copper Pot is where it is at if you like a good whiskey and far as beer the craft breweries in Canada are just kicking azz.
This just allows more time for the MM's to accumulate and then activate the spring coil. I'm convinced that we will close one day in pennyland and open @ $2.50 before the tremendous run to double digits.
Spreading false information on another board is misleading and unprofessional. You were better off admitting that you liquidated your position because you didn't believe where the company was going; open and honest....poor roofus.
idiot.
Surprised at the volume, I know it's a shortened day but I would have expected to see 3 or 4 million shares traded by now.
What happens to the share price if the U.S. government throws 500 million at Revive to ensure prescriptions are filled. 4-5 billion market cap.
News for - Pfizer/BioNTech
The U.S. government will pay $1.95 billion for the additional 100 million doses.
What a dangerous time to be short this stock. If we get positive news next week we will see these shorts scramble to cover, todays PR should have been a wake up call, maybe the unwinding of short positions happened yesterday and possibly today as the short report gets published twice a month. Todays PR was very encouraging and like most here Revive's CEO has continued to show a high level of professionalism.
For those analytics out there this is what I'm seeing;
RSI = 59 better
MACD approaching the signal line, this needs to stay above
20 DMA $0.50 CDN.
20 DMA $0.39 U.S.
Support level that needs to hold near term $0.52 CDN. 12/11/20
Support level that needs to hold near term $0.41 U.S. 12/11/20
After those points the chart is ugly and I won't post them. I'm still waiting for the Santa Claus rally and the euphoria that comes with it, I suspect it kicks off December 28th.
I'm expecting a sharp dip today when the market opens with volume and then accumulation. A news release next week could explain some of the volatility as traders were able to do some serious tree shaking. FDA feedback? Psychedelic news? We haven't heard any correspondence from Health Canada and with the current situation we could have bucillamine expedited to hospitals. My opinion/two cents but I have a good feeling, good luck investors I might add at the open if this prediction comes to fruition.
I love the enthusiasm on this board, revive will prosper and we will all reap the rewards of being in early, good luck investors.
100,000 share dump at 3:52
you don't think they are trying to shake the nervous nelly?
We are in this together, let all Revive value shareholders prosper.
Excellent DD Ecomike I like your analysis and foresight, newbies invest and sell on emotion and MM's know that, these large percentage dips are scare tactics. We are on the cusp of something very big here people, Revive is not a one trick pony.
Well there is Warren Buffet style of investing and your Jim Cramer FOMO crowd daytraders/chasers; know what you own - holding here and I might dip into a few more if the MACD turns up and RSI settles a little lower.
Overbought is a technical term Rio; fair value is what Morningstar sees the share price in 12 months your confusing the two, no worries. MM's & traders watch and trade according to the charts and candle's, let's hold our shares and/or add here. Revive is a gift.
Nice find; getting off the pinks is a big step this allows money managers to explore Revive, once completed we will see more analyst cover the company.
if we are fortunate we go sideways however the reasonable and logical direction is down until we get another news release, Indicators are signaling overbought MM's do not step in at this level......only news will drive this higher.
Hopefully your right, time will tell. We are definitely consolidating.
I'm expecting downward pressure this morning then an uptick before lunch. Volume is impressive but the news out is not getting any love.
Hey kmack49 not RS but (RSI) you misunderstood.
- Traditional interpretation and usage of the RSI are that values of 70 or above indicate that a security is becoming overbought or overvalued and may be primed for a trend reversal or corrective pullback in price. An RSI reading of 30 or below indicates an oversold or undervalued condition.
Ugly red candles as they indicate the price is going lower, look for a long red wick and then buy.
We've had a nice run and now RVV is consolidating and looking to make a new base. The only thing that bothers me is the stubbornly high RSI as it's sitting at 72. Chart guys normally exit positions on stocks above 70 and look to enter around 40 however with pending news in the background this can go parabolic anytime. Holding my shares tight and like most longs here waiting for multi dollars; $10 would be a blessing!
Love the energy Fress, keep it going, well done.
As much as you want to believe that RioDad "don't expect RVVTF to sell the company for $5.00" big pharma can easily ( or is ) accumulating behind the scene's. Stink bids/purchases happen all the time, we need to continue to see share price appreciation and let them chase this above $10.00
The IRB giving Revive the green light for compassionate use is some news that we can be expecting shortly as well.
IRB OK's Revive Therapeutics' compassionate use of Bucillamine in COVID-19
Sep. 16, 2020 9:10 AM ET Revive Therapeutics Ltd. (RVVTF)By: Mamta Mayani, SA News Editor14 Comments
Revive Therapeutics' (OTCPK:RVVTF) expanded access protocol (EAP) for compassionate use of Bucillamine in the treatment of COVID-19 received approval from the independent Institutional Review Board (IRB).
The EAP is being done to complement the Company’s Phase 3 COVID-19 study in the U.S. Revive expects patient enrollment in U.S. this month.
The objective is to monitor the safety and efficacy of Bucillamine (600 mg/day) and any clinical symptoms when administered up to 14 days in hospitalized patients with severe COVID-19. 14 and 42 days follow up assessment will be done after treatment completion.
The EAP for compassionate use provides physicians with access to Bucillamine under existing IND application for COVID-19.
That my friend is a fantastic post. What we do know is that Revive has the manufacturing and distribution already in place. We will know in coming days/weeks as leaks from the trials always happens, that will be our tell. We can forget about penny increments when the leak happens this will break the 52 week high on no news as we scratch are heads and then when the facts get announced....well we all know what happens.
Your cutting yourself short - 10 million patients per year? 10% of the U.S. population is 37 million add 10% of Canada 3.8 million and that's only North America.
if Revive gets FDA approval this goes parabolic. Wall street will immediately evaluate the potential revenue stream, I can't even make an educated guess where this tops out. Investors here guessing multi dollar but I can only say that with 240 million shares outstanding this will see multi million shares trading hands, hold your shares tight.
Hit the nail on the head. They could be getting a shot of vitamin 'C'
Media talking heads celebrating vaccine approvals yet! a large percentage of people are extremely nervous about taking it. The last survey out of the U.S. indicated 73% of respondents won't take the vaccine and 82% of the respondents don't trust big pharma. People's biggest fear are contractual agreements with their employer (take the vaccine or be fired). Revive's Bucillamine is a proven safe drug that needs more media attention and FDA approval (provided it works) I'm hoping that it does. The thought of taking proven medication (pill form) and removing the fear of injecting bunk weed is promising. 210 patients, let's see some darn results and let's catapult the share price and start saving lives.
So I did some digging into the uplisting on the OTCQB on the OTC markets website, this is not their first attempt for an application review and certification. If you scroll down to filings and disclosure you can see that they have been applying since 06/30/2015 under current directors with different positions.
Fabio Chianelli, CEO, Director 2015
Fabio Chianelli, President 2016
Fabio Chianelli, President 2017
Carmelo Marrelli, CFO 2018
Michael Frank, CEO 2020
Where the others have failed I believe Michael will succeed especially with their portfolio, but the time frame is irrelevant as history shows the OTC ensures they do their due diligence. On a positive note let's hope we hear about the results of the 210 patient enrollment and a FDA approval.
There is definitely an abundance of potential news in the pipeline but I think we drift here for a few weeks as the company collects trial data. The uplisting could be at the forefront before October closes out. GL.
very good read and the article sums up what most of us longs know already, waiting for data on effectiveness and news about a major partner would be icing on the cake.
let's focus on the interview this afternoon and see if Michael gives us any hints on patient trials. I still believe October will be the month that drives the shares up past the 52 week high and eventually into dollar land. Keep the board clean people.
We should be hearing about patient enrollment by the end of next week followed by data by the end of October.
We will get our day in the sun and when it happens look out as volume and share price will accelerate 1000% plus.
Really surprised with the lack of love Revive is getting from the market, I assume the MM's are waiting for substantial news regarding the trials as the latest news releases have been stellar.
What I find interesting is Trump continuing his contradicting language around a Covid vaccine for every American by April next year, yet the DC Director Dr. Robert Redfield said earlier this week that a vaccine wouldn’t be widely available until the summer or early fall of next year. That’s in line with predictions from public health experts and scientists, who have previously said that most Americans likely won’t get immunized with a coronavirus vaccine until the middle of next year.
WHO says virus ‘is not going away’
A top World Health Organization official said the coronavirus is “not going away,” noting that it’s still killing about 50,000 people a week.
“It has not burned out, it is not burning out, it is not going away,” Mike Ryan, executive director of the WHO’s emergencies program, said, “and especially for those countries entering their winter season in terms of people coming together more indoors.”
“That is not where we want to be,” he added.
Dr. Maria Van Kerkhove, the WHO’s technical lead on the Covid-19 pandemic, noted that global health officials have “literally hundreds” of studies ongoing that examine the extent of coronavirus infection in different populations. The studies indicate that “a majority of the world’s population is susceptible to infection from this virus,” she said. –Berkeley Lovelace Jr., Noah Higgins-Dunn
Added this morning, I'm still can't believe the share price.
Infections and reported numbers are dangerously climbing again around the world with some countries clawing back on gatherings and travel with some governments warning of potential lockdowns again. The fall season is knocking on the door in North America and we may see a vicious upswing in cases.